BRÈVE

sur DIAGNOSTIC MEDICAL (EPA:ALDMS)

Second quarter 2026 revenue for Diagnostic Medical Systems

Graphique de l'évolution du cours de l'action DIAGNOSTIC MEDICAL (EPA:ALDMS).

Diagnostic Medical Systems (DMS) reported revenue of €12.2 million for the second quarter of 2026, a 4% decrease compared to the previous year. This decline is primarily due to delivery delays in Ukraine and weaker demand for radiology services in Europe.

This quarter was nonetheless marked by a 32% increase in bone densitometry, offsetting a difficult start to the year. The radiology sector saw strong performance, with a 36% increase in private label sales. However, white label sales declined, impacting overall results.

DMS Group, which remains optimistic, anticipates a recovery in the second half of the year, with renewed ambitions in the international market, particularly thanks to the introduction of the ONYX system in Europe. The €4 million in financing received from the EIB is intended to support these future projects.

R. E.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de DIAGNOSTIC MEDICAL